Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

human papillomavirus vaccine, quadrivalent (Rx)Brand and Other Names:Gardasil, hpv vaccine, quadrivalent

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

vaccine

  • 0.5mL (single-dose vial)
more...

Prevention of Diseases Caused by HPV Types 6, 11, 16, & 18

0.5 mL IM x3 doses administered at 0, 1-2, & 6 months

For more vaccine information see http://www.cdc.gov/vaccines/schedules/hcp/index.html

Indicated for prevention in girls & women (9-26 years)

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 & 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • CDC recommends 3-dose series for routine vaccination for girls at age 11-12 yr
  • Catch-up vaccination: 3-dose series for those aged 13 through 26 yr
  • If age 26 yr reached before vaccination series completed, remaining doses can be administered after age 26 yr (CDC guidelines)

Precancerous or dysplastic lesions in girls & women (9-26 years) caused by HPV types 6, 11, 16, & 18

  • Cervical intraepithelial neoplasia grade 2/3
  • Cervical adenocarcinoma in situ
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2/3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2/3

Indicated for prevention in boys & men (9-26 years)

  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • CDC ACIP guidelines recommends routine immunization for all boys aged 11-12 years (MMWR Dec 23, 2011/Vol 60[50];1705-8)
  • Catch-up vaccination: 3-dose series for those aged 13 through 21 yr
  • Also, recommended for previously unvaccinated males aged 22–26 years who are immunocompromised, test positive for HIV infection, or who have sex with men

Anal cancer

  • Indicated for prevention of anal cancer and associated precancerous lesions caused by HPV types 6, 11, 16, and 18 people aged 9-26 years

Administration

Administer in deltoid region of upper arm or higher anterolateral area of thigh

Dosage Forms & Strengths

vaccine

  • 0.5mL (single-dose vial)
more...

Prevention of Diseases Caused by HPV Types 6, 11, 16, & 18

0.5 mL IM x 3 doses at 1, 1-2, and 6 months

For more vaccine information see http://www.cdc.gov/vaccines/schedules/hcp/index.html

CDC recommendations

  • CDC recommends routine vaccination for females at age 11 or 12 yr with either HPV2 or HPV4; may begin vaccination series as early as age 9 yr

Indicated for prevention in girls & women (9-26 years)

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 & 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • Catch-up vaccination: 3-dose series for those aged 13 through 26 yr
  • If age 26 yr reached before vaccination series completed, remaining doses can be administered after age 26 yr (CDC guidelines)

Precancerous or dysplastic lesions in girls & women (9-26 years) caused by HPV types 6, 11, 16, & 18

  • Cervical intraepithelial neoplasia grade 2/3
  • Cervical adenocarcinoma in situ
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2/3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2/3

Indicated for prevention in boys & men (9-21 years)

  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • Catch-up vaccination: 3-dose series for those aged 13 through 21 yr

Anal cancer

  • Indicated for prevention of anal cancer and associated precancerous lesions caused by HPV types 6, 11, 16, and 18 people aged 9-26 years
Next

Interactions

Interaction Checker

human papillomavirus vaccine, quadrivalent and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Inj site pain

            Inj site erythema & swelling

            Fever

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Age <9 yr or >26 yr

            Bleeding disorder, anticoagulant therapty (unless benefits outweigh risks)

            Cautions

            Individuals who develop symptoms indicative of hypersensitivity after 1st dose should not receive additional doses

            Monitor for 15 min following vaccination for syncope/convulsive syncope

            Not shown to be protective against non-vaccine HPV types

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: B; Not recommended for use in pregnant women

            Women who become pregnant after initiating the vaccination series, no intervention is needed; delay the remaining doses until completion of pregnancy

            Lactation: not known whether excreted in breast milk, use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Duration: unknown

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Mechanism of Action

            Recombinant vaccine prepared from L1 protein of HPV types 6, 11, 16 & 18

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.